| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $33.4M | +213.8% |
| SG&A Expense | $6.8M | +9.7% |
| Operating Income | -$40.2M | -138.7% |
| Net Income | -$39.7M | -1529.3% |
| EPS (Basic) | -$22.61 | — |
| EPS (Diluted) | -$22.61 | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $6.1M | -54.0% |
| Short-term Investments | $34K | +2.1% |
| Current Assets | $9.2M | -51.4% |
| Total Assets | $9.2M | -51.4% |
| Current Liabilities | $10.4M | +369.3% |
| Total Liabilities | $10.4M | +330.9% |
| Stockholders' Equity | -$1.3M | -107.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$28.1M | -3.4% |
| Investing Cash Flow | -$702 | -1.3% |
| Financing Cash Flow | $20.9M | -24.9% |